JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA.
Antimicrob Agents Chemother. 2010 Sep;54(9):4009-11. doi: 10.1128/AAC.01812-09. Epub 2010 Jul 12.
The activity of CEM-101, a fluoroketolide, was compared to those of 11 other antimicrobial agents using the reference broth microdilution method tested against 103 Neisseria meningitidis strains, including ciprofloxacin-nonsusceptible isolates with confirmed gyrA (T91I) mutations. Among the tested isolates, 79.6% were serogroup B or C and all isolates were susceptible to ceftriaxone, azithromycin, minocycline, and rifampin. However, penicillin-nonsusceptible strains were observed (15.5%) and susceptibility to trimethoprim-sulfamethoxazole was only 50.5%. CEM-101 was the most active macrolide-like compound (MIC(90), < or = 0.015 microg/ml) compared with MIC(90)s of telithromycin (MIC(90), 0.03 microg/ml), azithromycin and clarithromycin (MIC(90), 0.12 microg/ml), and erythromycin (MIC(90), 0.25 microg/ml). CEM-101 could provide a potent alternative for the prophylaxis of meningococcal disease.
氟喹诺酮 CEM-101 的活性与 11 种其他抗菌药物进行了比较，采用参考肉汤微量稀释法对 103 株脑膜炎奈瑟菌菌株进行了检测，包括经证实存在 gyrA（T91I）突变的环丙沙星不敏感分离株。在测试的分离株中，79.6%为血清组 B 或 C，所有分离株均对头孢曲松、阿奇霉素、米诺环素和利福平敏感。然而，观察到青霉素不敏感菌株（15.5%），对甲氧苄啶-磺胺甲恶唑的敏感性仅为 50.5%。与 MIC（90）分别为 0.03μg/ml 的泰利霉素、0.12μg/ml 的阿奇霉素和克拉霉素以及 0.25μg/ml 的红霉素相比，CEM-101 是最有效的大环内酯类化合物（MIC（90），≤0.015μg/ml）。CEM-101 可能为预防脑膜炎奈瑟菌病提供一种有效的替代药物。
